Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Stocktelligence May. 19 at 7:56 PM

$PPBT 3.47 fresh ATL

0 · Reply

R_Hobbs May. 19 at 7:50 PM

$PPBT what concerns me is why these big players are waiting for their warrants (shares they don't have to buy unless this strikes gold) instead of buying WAY cheaper if this a guarantee? Wouldn't that cost them millions? I mean I'd like to enter raffles and only pay for the ticket if they draw my name. 🤷

1 · Reply

Smittysixty May. 19 at 7:23 PM

$PPBT If a major M&A event hits, the only people who benefit are: • Management (equity at $5.60) • Institutions (warrants at $10) • Shareholders Hedge funds without warrants get nothing unless they own actual shares. So they need your shares. And they need them cheap. That’s why the FUD is nonstop.

0 · Reply

Smittysixty May. 19 at 7:23 PM

$PPBT The big institutions — Intercoastal, Susquehanna, Orca, Lincoln — already have guaranteed upside through their warrants. Their positions are locked in. But many hedge funds? They have no warrants. No protection. No guaranteed slice of the deal. So what’s their only path to profit? Convince retail to give up shares. That’s where the games begin.

0 · Reply

Purplepayday May. 19 at 7:18 PM

$PPBT Here is a hint Smitty If you own more than 5% of a publicly traded company's stock, you are considered a beneficial owner. You must make an ownership filing with the US Securities and Exchange Commission (SEC) within 5 business days of crossing the 5% threshold.

0 · Reply

Winorbust May. 19 at 7:17 PM

$PPBT Smitty doesn’t care about facts. He purposefully doesn’t speak about any specifics with his numbers because he just want the numbers to mislead people. @Purplepayday

0 · Reply

Winorbust May. 19 at 7:15 PM

$PPBT yes, and they should be sued! Blatant lies and misleading statements to basically manipulate the stock price And fiduciary duty to shareholders which they have failed miserably

0 · Reply

Smittysixty May. 19 at 7:15 PM

$PPBT The real question is: Why is nearly half the float rotating at the exact moment the company has: • FDA‑approval ready assets • A platform in Big Pharma’s acquisition zone • Management equity aligned • Institutional warrants at $10 • A tiny float • A strategic window open This isn’t normal. This is positioning. And the volume and price action is screaming it.

0 · Reply

Smittysixty May. 19 at 7:13 PM

$PPBT High Turnover + Low Price = Someone Absorbing When you see: • Huge volume • Tiny float • Price held down …it usually means one thing: Someone is absorbing shares quietly while the price is suppressed. That’s how accumulation works. That’s how positioning works. That’s how pre‑M&A setups look

0 · Reply

Smittysixty May. 19 at 7:12 PM

$PPBT This Is What Happens Before Big Events High float turnover in a tiny biotech almost always signals one thing: Positioning. Funds don’t churn 40% of a float for fun. They do it when: • A catalyst is near • A valuation event is expected • A strategic transaction is on the table • They want to secure shares before news hits This is classic pre‑event behavior.

0 · Reply

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

2026-03-25T12:17:12.000Z - 7 weeks ago

Purple Biotech announces collaboration with Converge Bio

2026-03-17T11:31:37.000Z - 2 months ago

Purple Biotech regains compliance with Nasdaq

2026-03-13T17:47:18.000Z - 2 months ago

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

2026-03-13T12:13:32.000Z - 2 months ago

Purple Biotech CEO Gil Efron to step down in August

2026-03-13T12:07:41.000Z - 2 months ago

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

Fri, 13 Mar 2026 08:04:00 -0400 - 2 months ago

Purple Biotech Announces CEO Transition

2026-02-28T00:50:34.000Z - 2 months ago

Purple Biotech trading halted, news pending

2026-02-25T22:35:50.000Z - 2 months ago

Purple Biotech to implement ADS ratio change

Wed, 25 Feb 2026 16:20:00 -0500 - 2 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

2026-01-07T13:05:42.000Z - 4 months ago

Purple Biotech completes toxicology study of IM1240

2025-12-11T12:26:28.000Z - 5 months ago

Purple Biotech’s antibody platform shows anti-tumor activity

Dec 4, 2025, 7:00 AM EST - 5 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

2025-11-14T13:11:08.000Z - 6 months ago

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

2025-11-14T13:10:49.000Z - 6 months ago

Purple Biotech sees cash runway into 1H27

Nov 14, 2025, 8:00 AM EST - 6 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-29T13:21:27.000Z - 7 months ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

2025-10-29T11:41:23.000Z - 7 months ago

Purple Biotech achieves manufacturing milestone for IM1240

Oct 29, 2025, 7:33 AM EDT - 7 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

2025-10-20T20:05:22.000Z - 7 months ago

Purple Biotech receives noncompliance notification from Nasdaq

Oct 20, 2025, 4:00 PM EDT - 7 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

2025-09-10T12:10:31.000Z - 8 months ago

Purple Biotech receives intention to grant a European patent covering NT219

Sep 5, 2025, 4:00 PM EDT - 9 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

2025-09-04T13:20:09.000Z - 9 months ago

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

2025-09-04T11:20:09.000Z - 9 months ago

Purple Biotech announces new data on IM1240

PPBT

2025-09-03T11:06:00.000Z - 9 months ago

Purple Biotech expands CAPTN-3 portfolio with IM1305

PPBT

2025-08-29T13:20:14.000Z - 9 months ago

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

PPBT

Aug 27, 2025, 7:00 AM EDT - 9 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-06T11:21:25.000Z - 10 months ago

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

PPBT

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 10 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 11 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 2 years ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 2 years ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Stocktelligence May. 19 at 7:56 PM

$PPBT 3.47 fresh ATL

0 · Reply

R_Hobbs May. 19 at 7:50 PM

1 · Reply

Smittysixty May. 19 at 7:23 PM

0 · Reply

Smittysixty May. 19 at 7:23 PM

0 · Reply

Purplepayday May. 19 at 7:18 PM

0 · Reply

Winorbust May. 19 at 7:17 PM

$PPBT Smitty doesn’t care about facts. He purposefully doesn’t speak about any specifics with his numbers because he just want the numbers to mislead people. @Purplepayday

0 · Reply

Winorbust May. 19 at 7:15 PM

$PPBT yes, and they should be sued! Blatant lies and misleading statements to basically manipulate the stock price And fiduciary duty to shareholders which they have failed miserably

0 · Reply

Smittysixty May. 19 at 7:15 PM

0 · Reply

Smittysixty May. 19 at 7:13 PM

0 · Reply

Smittysixty May. 19 at 7:12 PM

0 · Reply

Purplepayday May. 19 at 7:04 PM

$PPBT Yes… But 350K of those shares is dilution!

0 · Reply

Smittysixty May. 19 at 7:01 PM

$PPBT Since April 1st, nearly 400,000 shares have traded. The entire float is 930,000 shares. That means over 40% of the float has rotated in just a few weeks. In micro‑cap biotech land, that is not normal. That is accumulation behavior.

0 · Reply

Purplepayday May. 19 at 7:00 PM

$PPBT Did you just ignore the dilution or what Smitty ? 👇

0 · Reply

Smittysixty May. 19 at 6:48 PM

$PPBT Management equity was just approved in December at $5.60 — for the first time ever. Diluting now would: • Devalue their own equity • Reduce their payout in a • Undercut the alignment they just fought to secure Management finally has skin in the game. Dilution would hurt them directly.

1 · Reply

Smittysixty May. 19 at 6:48 PM

$PPBT Biotechs dilute when they’re early, unproven, and need cash to survive. But once a company reaches the point where: • Two assets are FDA‑approval‑ready • A platform is in Big Pharma’s acquisition zone • Management equity is finally aligned • Institutions hold high‑strike warrants …dilution stops being the playbook. Monetization becomes the playbook.

0 · Reply

Purplepayday May. 19 at 6:34 PM

$PPBT The ATM machine is still spewing out more shares, so they can get in their last $1 million before the warrants get’s lowered 👍

0 · Reply

Purplepayday May. 19 at 6:21 PM

$PPBT Non of them have a bought any shares at $5.6 or at$10 They only have an option to purchase them! Keep FACT in mind … Not FUD 👍

0 · Reply

Smittysixty May. 19 at 6:14 PM

$PPBT Insiders priced at $5.60. Institutions positioned at $10. Stock trading far below both. That’s not random. That’s not fear. That’s a disconnect — the kind that only exists before something big. The people with the most information are positioned above today’s price. That tells you everything about where the real incentives point.

0 · Reply

Purplepayday May. 19 at 6:13 PM

$PPBT It’s crazy that we had 35% dilution with around 350K new shares in the last 2 month…. And absolutely no tute have made a filling of ownership of more than 5%. …. NOT A SINGLE ONE ! That must get anyone here down from their Bullish chair… Don’t you think Smitty ?

0 · Reply

Smittysixty May. 19 at 6:13 PM

$PPBT When they’re trying this hard to push people out, the last thing they want is retail staying focused, informed, and steady. They don’t want strength. They don’t want conviction. They don’t want anyone recognizing the setup for what it is.

0 · Reply

Smittysixty May. 19 at 6:12 PM

$PPBT If you’re a retail trader like me, you’ve watched hedge funds and market makers play games with this ticker for years — walking it down, shaking out weak hands, and trying to separate retail from their hard‑earned positions. They want frustration. They want exhaustion. They want capitulation.

0 · Reply

Randy_Lahey_Trevor_Corey May. 19 at 6:11 PM

$PPBT can we sue these faggots

0 · Reply

Market Cap	5.06M
Revenue (ttm)	0.00
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	20,165
Avg Vol	11,292
Day's Range	N/A - N/A
Shares Out	1.29M
Stochastic %K	36%
Beta	0.68
Analysts	Sell
Price Target	$30.00